Super Method Seeks Cancer's Kryptonite
The application of CRISPR on a genome-wide scale provides a major insight into tumor dependency.
Jonathan James | | Longer Read
Decades of toil have led to significant breakthroughs in cancer diagnosis and treatment (1) – and many genetic loci have been pinpointed as key players in tumor development. But the search for more personalized therapy continues. Here, the combination of genome-wide CRISPR and computational biology may prove to be a powerful tool.
Fiona Behan is a Senior Scientist at the Wellcome Sanger Institute in Cambridge. With significant experience in genome-wide CRISPR, she was keen to apply the technology to oncology. “Collaborating with Kosuke Yusa, who was one of the leaders in developing genome-scale CRISPR technology, and Mathew Garnett, who had expertise in high-scale cancer screening, provided us with a great starting point for our research (2),” says Behan.
Read the full article now
Log in or register to read this article in full and gain access to The Translational Scientist’s entire content archive. It’s FREE!
Or register now - it’s free!
You will benefit from:
- Unlimited access to ALL articles
- News, interviews & opinions from leading industry experts